Related Experiment Video
Updated: Dec 9, 2025

Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease
Published on: July 3, 2018
D-dimer is associated with the risk of mortality in Coronavirus Disease 2019 patients
1Department of Epidemiology, School of Public Health, Zhengzhou University, Zhengzhou, China. yhy@zzu.edu.cn.
Insights
Elevated D-dimer levels in coronavirus disease 2019 (COVID-19) patients indicate a higher risk of mortality. This meta-analysis confirms a significant association between higher D-dimer levels and increased mortality risk in COVID-19 survivors.
Area of Science:
- Medical research
- Hematology
- Infectious diseases
Background:
- Coronavirus disease 2019 (COVID-19) is a global health crisis.
- Understanding prognostic markers for COVID-19 mortality is crucial.
Purpose of the Study:
- To investigate the association between D-dimer levels and mortality risk in COVID-19 patients.
- To synthesize existing evidence through a meta-analysis.
Main Methods:
- Meta-analysis of relevant studies.
- Comparison of D-dimer levels between survival and non-survival COVID-19 patient groups.
Main Results:
- D-dimer levels were significantly higher in non-survival COVID-19 patients compared to survival patients.
- A standardized mean difference (SMD) of 0.91 (95% CI = 0.79 to 1.03) indicated a substantial difference.
Conclusions:
- Elevated D-dimer levels are associated with an increased risk of mortality in COVID-19 patients.
- D-dimer serves as a potential prognostic biomarker for COVID-19 outcomes.
Abstract:
This study aims to investigate the association between D-dimer and the risk of mortality in coronavirus disease 2019 (COVID-19) patients using a meta-analysis. We found that the D-dimer levels in non-survival patients were significantly higher than those in survival patients (SMD = 0.91, 95% CI = 0.79 to 1.03). In conclusion, the elevated D-dimer levels were associated with an increased risk of mortality in COVID-19 patients.
Related Concept Videos
Cardiomyopathy II: Dilated Cardiomyopathy
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Coronary Artery Disease III: Clinical Manifestations
Acute Coronary Syndrome III: Diagnostic Studies
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Pulmonary Embolism I: Introduction
